Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 138

1.

The generation, detection, and effects of reactive drug metabolites.

Stachulski AV, Baillie TA, Park BK, Obach RS, Dalvie DK, Williams DP, Srivastava A, Regan SL, Antoine DJ, Goldring CE, Chia AJ, Kitteringham NR, Randle LE, Callan H, Castrejon JL, Farrell J, Naisbitt DJ, Lennard MS.

Med Res Rev. 2013 Sep;33(5):985-1080. doi: 10.1002/med.21273. Epub 2012 Oct 22. Review.

PMID:
23090860
2.

Pharmacokinetic-pharmacodynamic modeling of mood and withdrawal symptoms in relation to plasma concentrations of methadone in patients undergoing methadone maintenance treatment.

Shiran MR, Lennard MS, Iqbal MZ, Lagundoye O, Seivewright N, Tucker GT, Rostami-Hodjegan A.

J Clin Psychopharmacol. 2012 Oct;32(5):666-71. doi: 10.1097/JCP.0b013e3182664ecd.

PMID:
22926601
3.

Determination of a quantitative relationship between hepatic CYP3A5*1/*3 and CYP3A4 expression for use in the prediction of metabolic clearance in virtual populations.

Barter ZE, Perrett HF, Yeo KR, Allorge D, Lennard MS, Rostami-Hodjegan A.

Biopharm Drug Dispos. 2010 Nov;31(8-9):516-32. doi: 10.1002/bdd.732.

PMID:
21104927
4.

Characterisation of zuclopenthixol metabolism by in vitro and therapeutic drug monitoring studies.

Davies SJ, Westin AA, Castberg I, Lewis G, Lennard MS, Taylor S, Spigset O.

Acta Psychiatr Scand. 2010 Dec;122(6):444-53. doi: 10.1111/j.1600-0447.2010.01619.x. Epub 2010 Oct 12.

PMID:
20946203
5.

Contribution of the activities of CYP3A, CYP2D6, CYP1A2 and other potential covariates to the disposition of methadone in patients undergoing methadone maintenance treatment.

Shiran MR, Lennard MS, Iqbal MZ, Lagundoye O, Seivewright N, Tucker GT, Rostami-Hodjegan A.

Br J Clin Pharmacol. 2009 Jan;67(1):29-37. doi: 10.1111/j.1365-2125.2008.03312.x.

6.

Single-dose pharmacokinetic study of clomiphene citrate isomers in anovular patients with polycystic ovary disease.

Ghobadi C, Mirhosseini N, Shiran MR, Moghadamnia A, Lennard MS, Ledger WL, Rostami-Hodjegan A.

J Clin Pharmacol. 2009 Feb;49(2):147-54. doi: 10.1177/0091270008328096. Epub 2008 Nov 25.

PMID:
19033451
7.

CYP2D6 is primarily responsible for the metabolism of clomiphene.

Ghobadi C, Gregory A, Crewe HK, Rostami-Hodjegan A, Lennard MS.

Drug Metab Pharmacokinet. 2008;23(2):101-5.

8.

Evaluation of the relationship between plasma concentrations of en- and zuclomiphene and induction of ovulation in anovulatory women being treated with clomiphene citrate.

Ghobadi C, Amer S, Lashen H, Lennard MS, Ledger WL, Rostami-Hodjegan A.

Fertil Steril. 2009 Apr;91(4):1135-40. doi: 10.1016/j.fertnstert.2008.01.058. Epub 2008 Mar 18.

PMID:
18353317
9.

Inactivation of CYP2D6 by methylenedioxymethamphetamine in different recombinant expression systems.

Van LM, Hargreaves JA, Lennard MS, Tucker GT, Rostami-Hodjegan A.

Eur J Pharm Sci. 2007 Sep;32(1):8-16. Epub 2007 May 22.

PMID:
17574396
10.

PRN prescribing in psychiatric inpatients: potential for pharmacokinetic drug interactions.

Davies SJ, Lennard MS, Ghahramani P, Pratt P, Robertson A, Potokar J.

J Psychopharmacol. 2007 Mar;21(2):153-60. Erratum in: J Psychopharmacol. 2008 Aug;22(6):698.

PMID:
17329294
11.

The use of mechanistic DM-PK-PD modelling to assess the power of pharmacogenetic studies -CYP2C9 and warfarin as an example.

Dickinson GL, Lennard MS, Tucker GT, Rostami-Hodjegan A.

Br J Clin Pharmacol. 2007 Jul;64(1):14-26. Epub 2007 Feb 12.

12.
13.

Editors' review of 2006 and the BJCP prize.

Aronson JK, Lennard MS, Ritter JM, Begg EJ, Lewis LD, Schachter M.

Br J Clin Pharmacol. 2007 Jan;63(1):1-4. Review. No abstract available.

14.

Evaluation of an existing nomogram for predicting the response to clomiphene citrate.

Ghobadi C, Nguyen TH, Lennard MS, Amer S, Rostami-Hodjegan A, Ledger WL.

Fertil Steril. 2007 Mar;87(3):597-602. Epub 2006 Dec 6.

PMID:
17156783
15.

Does previous response to clomifene citrate influence the selection of gonadotropin dosage given in subsequent superovulation treatment cycles?

Nguyen TH, Lennard MS, Ghobadi C, Rostami-Hodjegan A, Ledger WL.

J Assist Reprod Genet. 2006 Nov-Dec;23(11-12):427-31. Epub 2006 Dec 3.

16.

Determination by liquid chromatography-mass spectrometry of clomiphene isomers in the plasma of patients undergoing treatment for the induction of ovulation.

Crewe HK, Ghobadi C, Gregory A, Rostami-Hodjegan A, Lennard MS.

J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Mar 1;847(2):296-9. Epub 2006 Nov 7.

PMID:
17085084
17.

A six-year evaluation of methadone prescribing practices at a substance misuse treatment centre in the UK.

Dickinson GL, Rostami-Hodjegan A, Lagundoye O, Seivewright N, Pratt P, Lennard MS.

J Clin Pharm Ther. 2006 Oct;31(5):477-84.

PMID:
16958826
18.

Solid-phase microextraction: investigation of the metabolism of substances that may be abused by inhalation.

Walker R, Flanagan RJ, Lennard MS, Mills GA, Walker V.

J Chromatogr Sci. 2006 Aug;44(7):387-93.

PMID:
16925936
19.

A critical evaluation of the experimental design of studies of mechanism based enzyme inhibition, with implications for in vitro-in vivo extrapolation.

Ghanbari F, Rowland-Yeo K, Bloomer JC, Clarke SE, Lennard MS, Tucker GT, Rostami-Hodjegan A.

Curr Drug Metab. 2006 Apr;7(3):315-34. Review.

PMID:
16611025
20.

Design, synthesis and evaluation of furanocoumarin monomers as inhibitors of CYP3A4.

Row EC, Brown SA, Stachulski AV, Lennard MS.

Org Biomol Chem. 2006 Apr 21;4(8):1604-10. Epub 2006 Mar 20.

PMID:
16604230
21.

Characterization of the human cytochrome P450 forms involved in metabolism of tamoxifen to its alpha-hydroxy and alpha,4-dihydroxy derivatives.

Notley LM, Crewe KH, Taylor PJ, Lennard MS, Gillam EM.

Chem Res Toxicol. 2005 Oct;18(10):1611-8.

PMID:
16533026
22.

Synthesis of 8-geranyloxypsoralen analogues and their evaluation as inhibitors of CYP3A4.

Row EC, Brown SA, Stachulski AV, Lennard MS.

Bioorg Med Chem. 2006 Jun 1;14(11):3865-71. Epub 2006 Feb 14.

PMID:
16481174
23.

The impact of experimental design on assessing mechanism-based inactivation of CYP2D6 by MDMA (Ecstasy).

Van LM, Heydari A, Yang J, Hargreaves J, Rowland-Yeo K, Lennard MS, Tucker GT, Rostami-Hodjegan A.

J Psychopharmacol. 2006 Nov;20(6):834-41. Epub 2006 Feb 14.

PMID:
16478752
24.

Development of novel furanocoumarin dimers as potent and selective inhibitors of CYP3A4.

Row E, Brown SA, Stachulski AV, Lennard MS.

Drug Metab Dispos. 2006 Feb;34(2):324-30. Epub 2005 Nov 18.

25.

Can saliva replace plasma for the monitoring of methadone?

Shiran MR, Hassanzadeh-Khayyat M, Iqbal MZ, Lagundoye O, Seivewright N, Lennard MS, Tucker GT, Rostami-Hodjegan A.

Ther Drug Monit. 2005 Oct;27(5):580-6.

PMID:
16175130
26.

Potential for drug interactions involving cytochrome P450 in patients attending palliative day care centres: a multicentre audit.

Wilcock A, Thomas J, Frisby J, Webster M, Keeley V, Finn G, Fossey K, Wee B, Beale J, Lennard MS.

Br J Clin Pharmacol. 2005 Sep;60(3):326-9.

27.
28.

The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. 1992.

Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE.

Br J Clin Pharmacol. 2004 Dec;58(7):S744-7; discussion 748-50. No abstract available.

29.

Mechanism-based inactivation of CYP2D6 by methylenedioxymethamphetamine.

Heydari A, Yeo KR, Lennard MS, Ellis SW, Tucker GT, Rostami-Hodjegan A.

Drug Metab Dispos. 2004 Nov;32(11):1213-7. Epub 2004 Aug 24.

30.

Monitoring plasma concentrations to individualize treatment with clomiphene citrate.

Rostami-Hodjegan A, Lennard MS, Tucker GT, Ledger WL.

Fertil Steril. 2004 May;81(5):1187-93.

PMID:
15136073
31.

Metabolism of ethylbenzene by human liver microsomes and recombinant human cytochrome P450s (CYP).

Sams C, Loizou GD, Cocker J, Lennard MS.

Toxicol Lett. 2004 Mar 7;147(3):253-60.

PMID:
15104117
32.
33.
34.

A discordance between cytochrome P450 2D6 genotype and phenotype in patients undergoing methadone maintenance treatment.

Shiran MR, Chowdry J, Rostami-Hodjegan A, Ellis SW, Lennard MS, Iqbal MZ, Lagundoye O, Seivewright N, Tucker GT.

Br J Clin Pharmacol. 2003 Aug;56(2):220-4.

35.

mRNA and protein expression of dog liver cytochromes P450 in relation to the metabolism of human CYP2C substrates.

Graham MJ, Bell AR, Crewe HK, Moorcraft CL, Walker L, Whittaker EF, Lennard MS.

Xenobiotica. 2003 Mar;33(3):225-37.

PMID:
12637241
36.

Determination of midazolam and 1'-hydroxymidazolam by liquid chromatography-mass spectrometry in plasma of patients undergoing methadone maintenance treatment.

Shiran MR, Gregory A, Rostami-Hodjegan A, Tucker GT, Lennard MS.

J Chromatogr B Analyt Technol Biomed Life Sci. 2003 Jan 5;783(1):303-7.

PMID:
12450551
38.

Influence of phenylalanine-481 substitutions on the catalytic activity of cytochrome P450 2D6.

Hayhurst GP, Harlow J, Chowdry J, Gross E, Hilton E, Lennard MS, Tucker GT, Ellis SW.

Biochem J. 2001 Apr 15;355(Pt 2):373-9.

39.

Parkinson's disease and CYP1A2 activity.

Forsyth JT, Grünewald RA, Rostami-Hodjegan A, Lennard MS, Sagar HJ, Tucker GT.

Br J Clin Pharmacol. 2000 Oct;50(4):303-9.

40.

The 1'-hydroxylation of Rac-bufuralol by rat brain microsomes.

Coleman T, Spellman EF, Rostami-Hodjegan A, Lennard MS, Tucker GT.

Drug Metab Dispos. 2000 Sep;28(9):1094-9.

41.

Halofantrine and chloroquine inhibit CYP2D6 activity in healthy Zambians.

Simooya OO, Sijumbil G, Lennard MS, Tucker GT.

Br J Clin Pharmacol. 1998 Mar;45(3):315-7.

42.

Regioselective hydroxylation of debrisoquine by cytochrome P4502D6: implications for active site modelling.

Lightfoot T, Ellis SW, Mahling J, Ackland MJ, Blaney FE, Bijloo GJ, De Groot MJ, Vermeulen NP, Blackburn GM, Lennard MS, Tucker GT.

Xenobiotica. 2000 Mar;30(3):219-33.

PMID:
10752638
43.

Evidence that serine 304 is not a key ligand-binding residue in the active site of cytochrome P450 2D6.

Ellis SW, Hayhurst GP, Lightfoot T, Smith G, Harlow J, Rowland-Yeo K, Larsson C, Mahling J, Lim CK, Wolf CR, Blackburn MG, Lennard MS, Tucker GT.

Biochem J. 2000 Feb 1;345 Pt 3:565-71.

44.

The antitussive effect of dextromethorphan in relation to CYP2D6 activity.

Abdul Manap R, Wright CE, Gregory A, Rostami-Hodjegan A, Meller ST, Kelm GR, Lennard MS, Tucker GT, Morice AH.

Br J Clin Pharmacol. 1999 Sep;48(3):382-7.

45.

Meta-analysis of studies of the CYP2D6 polymorphism in relation to lung cancer and Parkinson's disease.

Rostami-Hodjegan A, Lennard MS, Woods HF, Tucker GT.

Pharmacogenetics. 1998 Jun;8(3):227-38.

PMID:
9682268
46.

Oxidation of methamphetamine and methylenedioxymethamphetamine by CYP2D6.

Lin LY, Di Stefano EW, Schmitz DA, Hsu L, Ellis SW, Lennard MS, Tucker GT, Cho AK.

Drug Metab Dispos. 1997 Sep;25(9):1059-64.

47.

Cytochromes P450 mediating the N-demethylation of amitriptyline.

Ghahramani P, Ellis SW, Lennard MS, Ramsay LE, Tucker GT.

Br J Clin Pharmacol. 1997 Feb;43(2):137-44.

48.

Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes.

Crewe HK, Ellis SW, Lennard MS, Tucker GT.

Biochem Pharmacol. 1997 Jan 24;53(2):171-8.

PMID:
9037249
49.
50.

Variable contribution of CYP2D6 to the N-dealkylation of S-(-)-propranolol by human liver microsomes.

Rowland K, Ellis SW, Lennard MS, Tucker GT.

Br J Clin Pharmacol. 1996 Sep;42(3):390-3.

Supplemental Content

Loading ...
Support Center